Zymergen — Merger or Acquisition (July 2022)
16 slides from Zymergen's merger presentation, Jul 25, 2022
Slide 1: M&A Strategy Update: Accelerating scale to better deliver for our customers
Filed by Ginkgo Bioworks Holdings, Inc. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Zymergen Inc. Commission File No.: 001-40354 Date: July 25, 2022 M&A Strategy Update Accelerating scale to
Slide 2: Disclaimer: Forward Looking Statements
Disclaimer Forward Looking Statements This communication contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. You can generally identify forward-looking statements by the u
Slide 3: Disclaimer: Trademarks and Additional Information
Disclaimer Trademarks This presentation may contain trademarks, service marks, trade names and copyrights of other companies, which are the property of their respective owners, and Ginkgo’s use thereof does not imply an affiliation with, or endorsement by, the owners of such trademarks, service marks,
Slide 4: Our mission is to make biology easier to engineer
Our mission is to make biology easier to engineer.
Slide 5: Making biology easier to engineer for customers via our cell programming platform
We aim to make biology easier to engineer for our customers by leveraging our platform for programming cells M&A STRATEGY UPDATE - JULY 2022 Property of Ginkgo Bioworks — 5
Slide 6: Opportunistic in the current market while maintaining a margin of safety
We can be opportunistic in the current market environment, while still maintaining a healthy margin of safety Ginkgo is well positioned to continue to scale our platform, both organically and through M&A, in the current environment ● Strong balance sheet (approximately $1.5 billion as of 3/31/2022)
Slide 7: Successful history of integrating technology acquisitions
We have a successful history of integrating technology acquisitions and are able to use M&A as a tool to build both horizontal capabilities and vertical R&D expertise 1 Consumer & Pharma & Industrials & Food & Agriculture Biosecurity Technology Biotech Environment Nutrition 2019 2020 2021 2022 2022
Slide 8: Bayer represents a significant vertical expansion for the agricultural sector
1 Bayer represents a significant vertical expansion, enhancing our platform capabilities for the agricultural sector a b West Sacramento Acquisition Joyn Dissolution Cooksonia Bayer Bayer (70% owned by Ginkgo) 50% 50% $83M WestSac WestSac consideration R&D Site Platform assets (IP, team, etc) Facilit
Slide 9: Bayer partnership adds capabilities and new commercial opportunities
1 Bayer partnership adds both capabilities and new commercial opportunities to help make investments sustainable Illustrative Impact to Pro Forma P&L Ginkgo will take on some incremental operating expenses from the integration of Joyn and Bayer’s West Sacramento R&D Facility However, cost structure
Slide 10: Zymergen acquisition deepens horizontally applicable automation, software, data and strain engineering tools
2 Zymergen acquisition deepens horizontally applicable automation, software, data, and strain engineering tools, helping achieve scaling targets Transaction Summary Very strong automation and software team and robust technology stack supports platform scaling efforts All stock transaction, exchange r
Slide 11: Zymergen has a robust technology portfolio complementary to the Ginkgo platform
2 Zymergen has a robust technology portfolio, which will be a complementary addition to the Ginkgo platform ● Zymergen has made significant investments in advanced robotic automation and material conveyance Productivity improvements may drive down unit ● Flexible architecture is complementary to the
Slide 12: Ginkgo's vision fits well with where Zymergen is in its transformation
2 Ginkgo’s vision fits well with where Zymergen is in its transformation Over the last year, Zymergen has simplified Ginkgo’s expertise in creating and supporting NewCos its business into 3 core areas: Advanced will support Zymergen’s plans to explore standalone Materials, Drug Discovery, and Automati
Slide 13: Realizing benefits of the acquisition while managing incremental costs
2 We expect to be able to realize the benefits of this acquisition while managing incremental costs to reasonable levels 1 Pre-close, Zymergen plans to progress its previously and Illustrative Impact to Pro Forma OpEx independently planned cost and program rationalization ● Announced latest workforce
Slide 14: Zymergen not contributing meaningful revenue but improves technical capabilities
2 Unlike the Bayer transaction, Zymergen is not contributing meaningful revenue, but we believe there is significant value in improving our technical capabilities and value proposition to customers Supports platform scaling efforts by contributing a world-class team and robust technology stack Lowers
Slide 15: We're very excited about where we go from here
We’re very excited about where we go from here We’re excited to have signed these two acquisitions, which should significantly improve our vertical and horizontal platform capabilities for customers …but that was the easy part! ● We’ll be heavily focused on integration planning and execution over the
Slide 16: Let's build the world we want to see
Let’s build the world we want to see